Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials.
Fuente:
PubMed
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Journal of neuroimmunology
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1868266117059837953 |
|---|---|
| author | Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M |
| author_facet | Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M |
| collection | PubMed - marine biology |
| contents | Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials. Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M Alzheimer Disease Humans Seaweed Animals Microalgae Antioxidants Neuroprotective Agents Anti-Inflammatory Agents Alzheimer's disease (AD) is a progressive neurodegenerative disorder identified by cognitive decline, memory loss, and behavioral changes, affecting approximately 50 million people worldwide. Genetic predisposition, environmental variables, and aging all play a role in the development of AD. Current therapeutic approaches primarily focus on alleviating symptoms through drugs such as donepezil and memantine. However, these treatments offer limited efficacy and may be accompanied by adverse effects. In contrast, natural therapies derived from algae present a promising alternative. Microalgae, including Chlorella and Spirulina, and macroalgae such as Fucus vesiculosus, Ecklonia cava, Sargassum, Laminaria japonica, and Fucus species, are rich in bioactive molecules having antioxidant and anti-inflammatory characteristics. These substances demonstrated potential in addressing the pathological features of AD, such as oxidative stress and neuroinflammation. Furthermore, advances in biotechnological tools like CRISPR-Cas9 gene editing are poised to enhance the efficacy of these natural therapies by targeting and modifying disease-associated genes. This review aims to bridge the fields of neurobiotechnology and marine bioresources by examining the synergistic potential of algal compounds and gene-editing strategies in combating Alzheimer's disease. Algal-derived compounds are utilized in pharmaceuticals, nutraceuticals, and dietary supplements, and may offer neuroprotective benefits that could aid in the prevention or treatment of AD.By integrating insights from molecular biology, pharmacology, and genomics, we seek to illuminate a novel, multidisciplinary framework for future therapeutic innovation. |
| format | Artículo científico |
| id | pubmed_41338025 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Journal of neuroimmunology |
| record_format | pubmed |
| spellingShingle | Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials. Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M Alzheimer Disease Humans Seaweed Animals Microalgae Antioxidants Neuroprotective Agents Anti-Inflammatory Agents Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials. Wagdy, Merna Ibrahim, Abeer A Yahia, Alaa M Maher, Rola M Abo-Elwafa, Afaf Hany Salah, Alyaa Heikal, Yasmin M Alzheimer Disease Humans Seaweed Animals Microalgae Antioxidants Neuroprotective Agents Anti-Inflammatory Agents Alzheimer's disease (AD) is a progressive neurodegenerative disorder identified by cognitive decline, memory loss, and behavioral changes, affecting approximately 50 million people worldwide. Genetic predisposition, environmental variables, and aging all play a role in the development of AD. Current therapeutic approaches primarily focus on alleviating symptoms through drugs such as donepezil and memantine. However, these treatments offer limited efficacy and may be accompanied by adverse effects. In contrast, natural therapies derived from algae present a promising alternative. Microalgae, including Chlorella and Spirulina, and macroalgae such as Fucus vesiculosus, Ecklonia cava, Sargassum, Laminaria japonica, and Fucus species, are rich in bioactive molecules having antioxidant and anti-inflammatory characteristics. These substances demonstrated potential in addressing the pathological features of AD, such as oxidative stress and neuroinflammation. Furthermore, advances in biotechnological tools like CRISPR-Cas9 gene editing are poised to enhance the efficacy of these natural therapies by targeting and modifying disease-associated genes. This review aims to bridge the fields of neurobiotechnology and marine bioresources by examining the synergistic potential of algal compounds and gene-editing strategies in combating Alzheimer's disease. Algal-derived compounds are utilized in pharmaceuticals, nutraceuticals, and dietary supplements, and may offer neuroprotective benefits that could aid in the prevention or treatment of AD.By integrating insights from molecular biology, pharmacology, and genomics, we seek to illuminate a novel, multidisciplinary framework for future therapeutic innovation. |
| title | Neurobiotech innovative strategies targeting Alzheimer's disease through therapeutic micro and macroalgae potentials. |
| topic | Alzheimer Disease Humans Seaweed Animals Microalgae Antioxidants Neuroprotective Agents Anti-Inflammatory Agents |
| url | https://pubmed.ncbi.nlm.nih.gov/41338025/ |